- Indication
- Acne Vulgaris
- RAG rating
- Double Red
- Document type
- NICE technology appraisal
- Place
- Hertfordshire and West Essex ICB
- Output type
- Pharmacy / Prescribing
Clascoterone
Clascoterone (Winlevi®)
HERTFORDSHIRE AND WEST ESSEX AREA PRESCRIBING COMMITTEE (HWE APC)
Clascoterone for treating acne vulgaris
DOUBLE RED
Not recommended for prescribing by primary, community or secondary care.
Name generic (trade): Clascoterone (Winlevi®) cream
What it is: Topical androgen receptor inhibitor
Indication: Treating acne vulgaris in people 12 years and over
Date of decision: December 2025
NICE: NICE TA1105 – Terminated appraisal
HWE APC recommendation:
Treatment appraisal terminated by NICE.
HWE APC designated a "double red” category - Not recommended for prescribing in primary, community or secondary care.
NICE is unable to make a recommendation on clascoterone (Winlevi®) for treating acne vulgaris in people 12 years and over. The company (manufacturer) did not provide an evidence submission.
- Version number
- 1.0
- Developed by
- Pharmacy and Medicines Optimisation Team, Hertfordshire and West Essex (HWE) ICB with relevant HWE ICS stakeholders.
- Approved by
- Hertfordshire & West Essex Area Prescribing Committee
- Date approved / updated
- December 2025
- Review date
- This HWE APC recommendation is based upon the evidence available at the time of publication. This recommendation will be reviewed upon request in the light of new evidence becoming available.
- Superseded version
- NA